Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 9/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609358 | 0.91 | CYP2A6 (0.53) | OPRM1CYP2A6P2RX3PDE4BL3MBTL1 | |
| SCHEMBL3177956 | 0.85 | OPRM1 (0.58) | OPRM1P2RX3PDE4BL3MBTL1GAA | |
| SCHEMBL8016836 | 0.85 | OPRM1 (0.58) | OPRM1P2RX3PDE4BL3MBTL1GAA | |
| SCHEMBL8237112 | 0.83 | KDM4E (0.54) | OPRM1CYP2A6P2RX3PDE4BL3MBTL1 | |
| SCHEMBL3692227 | 0.82 | OPRM1 (0.62) | OPRM1P2RX3PDE4BL3MBTL1GAA | |
| SCHEMBL5830771 | 0.82 | OPRM1 (0.53) | OPRM1P2RX3PDE4BL3MBTL1GAA | |
| SCHEMBL8410055 | 0.80 | OPRM1 (0.57) | OPRM1P2RX3PDE4BL3MBTL1GAA | |
| SCHEMBL15604704 | 0.80 | CYP2A6 (0.76) | CYP2A6KDM4ERAB9A | |
| SCHEMBL24665295 | 0.80 | OPRM1 (0.52) | OPRM1P2RX3PDE4BL3MBTL1HTT | |
| SCHEMBL6160870 | 0.80 | MEN1 (0.58) | OPRM1P2RX3PDE4BL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1500658-A1 | NOVEL THIOL DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TST, QSOX1, MMP1 | OPRM1 2125/4885CYP2A6 587/4885P2RX3 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.